Moreover, other intracellular profibrogenic signalling pathways, including mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK), were also activated by CNI treatment [31, 32], which restricts the use of CNIs in the AKI-to-CKD transition. The gene discussed is WNK2; the disease is chronic kidney disease.